← Back to Search

Hormone Therapy

Intervention Group for Normal Cellular Metabolism

Phase 1
Waitlist Available
Led By K Sreekumaran Nair
Research Sponsored by K. Sreekumaran Nair
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ages 18-45
Able to provide written consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 hours
Awards & highlights

Study Summary

This study is evaluating whether a new method to measure the activity of the TCA cycle or flux directly in tissues of human beings can be used to study the activity of the TCA cycle in tissues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
In Vivo TCA cycle flux in skeletal muscle and splanchnic tissue
Secondary outcome measures
Changes in the metabolome derived from the arterial-venous blood supply of the skeletal muscle and splanchnic tissue
Changes in the protein and metabolite contents within circulating exosomes derived from the arterial-venous blood supply of the skeletal muscle and splanchnic tissue
Changes in the proteome derived from the arterial-venous blood supply of the skeletal muscle and splanchnic tissue in response to hormonal manipulation.
+3 more

Trial Design

2Treatment groups
Active Control
Group I: Control GroupActive Control1 Intervention
No somatostatin and glucagon infusions
Group II: Intervention GroupActive Control2 Interventions
Somatostatin and glucagon infusions

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

K. Sreekumaran NairLead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,357 Previous Clinical Trials
4,315,169 Total Patients Enrolled
K Sreekumaran NairPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
92 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Cell MetabolismJournal
Excessive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver Disease
Sunny, Nishanth E., Elizabeth J. Parks, Jeffrey D. Browning, and Shawn C. Burgess. 2011. “Excessive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver Disease”. Cell Metabolism. Elsevier BV. doi:10.1016/j.cmet.2011.11.004.
clinicaltrials.govStudy
In Vivo Assessment of Cellular Metabolism in Humans
K. Sreekumaran Nair 2016. "In Vivo Assessment of Cellular Metabolism in Humans". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02748369.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top